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ABST RACT
Morphea or localized scleroderma is an uncommon autoimmune and
inflammatory disease which affects patients of any age. Even if morphea
lesions present systemic symptoms as myalgias or arthritis, it is distinct from
systemic sclerosis because it does not associate Raynaud’s phenomena or
sclerodactyly, which are encountered in systemic scleroderma. The most
common form of morphea in children is `en coup de sabre`, which can alter
the local anatomy by deep tissue involvement. In contrast, the most frequent
form that affects adults is represented by circumscribed morphea. The initial
lesions present an inflammatory phase that manifests in the form of
erythematous plaques, sometimes accompanied by edema. In later stages, the
inflammation decreases and the lesions become sclerotic to atrophic. Therapy
is most beneficial when initiated in the inflammatory stage. Topical
application of high potency steroids along with phototherapy demonstrates
the best results in the active phase of the disease. Localized superficial
morphea can be treated with the excimer laser (using ultraviolet type B light,
in range of 308nm) if topical steroid administration shows no significant
clinical improvement. Phototherapy with ultraviolet light is capable of
decreasing inflammation and may also have immunomodulatory effects.

Introduction
Morphea or localized scleroderma is an uncommon
fibromatous disease of the connective tissue in the skin
and subdermal structures. The disease is characterized
by the production of excess collagen deposits in the
skin, causing its thickening [1]. The deposits of collagen
usually involve the reticular dermis (in the classical
form of morphea) but can expand into the subdermal
layer [2]. Superficial morphea (SM) is a particular/
uncommon entity characterized by a localized deposition
of additional collagen in the papillary dermis and upper
reticular dermis [3], being first described by McNiff in
1999 [4]. Patients who chose the excimer laser therapy
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generally have followed a 6-8-week treatment with
topical corticosteroids and often multiple sessions of
UVA treatment, all these options being used for antiinflammatory purposes. Basically, when patients
receive recommendation for UVB or UVB narrow
band, the excimer laser treatment represents a viable
therapeutic alternative for dermatologists. In
superficial morphea, the literature often describes
multiple hyperpigmented and slightly indurated patches
or plaques, distributed especially on the trunk and
intertriginous areas [5]. Occasionally, purple borders
may occur (suggesting the acute inflammatory phase),
as well as minimal atrophy and hypopigmented areas in
the hyperpigmentation spots [6].
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The clinical diagnosis of morphea can be confirmed
by histopathological examination which highlights the
excessive bundle deposits of thickened collagen in the
papillary dermis and reticular dermis. The purpose of the
therapy is to improve induration and hyperpigmentation,
to decrease inflammation, and to stop the progression of
the lesions.

Discussions
The term morphea was first used in Ancient Greece to
describe the form or structure of objects. Nowadays, the
entity of morphea refers to a chronic autoimmune disorder
related to unknown conditions, which has a genetic
predisposition, and which is characterized by sclerotic
changes in the skin. Another term for this disorder is
“localized scleroderma.”
It may be challenging to distinguish localized
scleroderma from scleroderma. Scleroderma, better
known as systemic sclerosis, is a distinct autoimmune
connective tissue disorder that can involve cutaneous
sclerosis and systemic manifestations other than those
observed in morphea.
Morphea is a fairly rare disease that can develop at
any age, but most often affects adults [7]. The ratio
between genders reflects a 3:1 fraction in favor of female
distribution [7]. The most frequent manifestation of the
disease in children represents the linear form, while for
adults the clinical expression is usually the circumscribed
plaques form. Regarding prevalence related to ethnicity,
Caucasians are more likely to suffer from the disease than
African-Americans [8]. The clinical appearance of
morphea could be as a single localized lesion, or a single
lesion which can affect half of the forehead (en coup de
sabre), or an extensive form affecting half of the body [9],
or in the form of a disseminated disease with multiple
localizations affecting the entire body [10]. The clinical
course of the disease may follow two paths. More
frequently, the disease activity may persist for 3-6 years.
In fewer cases, the disease activity can become persistent
and recurring.
Risk factors for developing the disease have been
described in various studies. The immune component,
which has an abnormal response to different triggers, is
thought to be the key element in the pathogenesis of
morphea. Different kinds of infectious episodes are
related to the onset of this inflammatory disorder of the
skin. As an example, studies performed in Europe have
revealed a connection between Borrelia infection and
morphea lesions [10,11]. These studies have noted high
levels of antibodies against Borrelia burgdorferi in
patients suffering from morphea. Another finding
demonstrated the presence of these microorganisms in
biopsies performed from lesions of morphea. Other
studies question this outcome and claim that a certain type

of morphea lesions could be caused by certain species of
Borrelia found only in Europe and Asia, but not identified
in the USA [12]. There have been reported cases of
morphea after administration of biological therapy with
ustekinumab, a human monoclonal antibody which blocks
interleukin (IL)-12 and IL-23 via P40, more specifically
their common protein subunit [13]. Other factors in the
etiology of morphea include cutaneous radiation, skin
trauma such as surgery or injections, and insect bites
[14,15].
Regarding pathogenesis, morphea is usually described
as an autoimmune-mediated inflammatory disease. The
inflammatory infiltrate shown in morpheic lesions is
composed from T lymphocytes, plasmocytic cells, and
eosinophils. Laboratory tests performed on morphea
patients have revealed high levels of autoimmune
antibodies, especially antinuclear antibodies. The key
element in the pathogenesis of morphea is the increased
production of collagen types I and III. This production is
generated by platelet-derived growth factor, connective
tissue growth factor, and matrix metalloproteinases [16].
All these factors decrease gamma interferon, a suppressor
of collagen synthesis.
The morpheic lesions develop insidiously and arise as
erythematous edematous plaques due to the initial
inflammatory process. In time, the center of the lesion
becomes sclerous and the periphery of the lesion
highlights a violaceus border. Sclerotic lesions are
characterized by follicular atrophy and hypo/
hyperpigmentation, and eventually the lesions become
atrophic.
Subtypes of morphea include circumscribed (plaques)
morphea lesions, linear, deep, and generalized. The
circumscribed form is most common in adults and it
presents with indurated round-oval plaques. The linear
form, which mostly affects children, occurs with
morpheic form plaques arranged in linear distribution. En
coup de sabre lesions involve morpheic lesions to the
cephalic region. It resembles the cut of a sword and
manifests as a linear atrophic plaque. Although it usually
affects the forehead, its progression to the scalp may
induce scarring alopecia. The generalized morphea is
manifested by the presence of at least 4 plates, on at least
two anatomical sites. Contrary to the systemic sclerosis,
generalized morphea does not involve Raynaud’s
phenomenon, sclerodactyly, and capillary changes
observed at capillaroscopy [17]. The deep morphea
subtype refers to the deep dermis and subcutaneous tissue
involvement.
Systemic symptoms related to morphea include
carpal tunnel syndrome and muscular and skeletal
involvement such as arthritis and myalgias. En coup de
sabre lesions may produce neurological and ocular
complications. The coexistence of SM with other skin
47
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diseases is uncommon. Saleh and Colab reported the
case of a patient who presented both psoriasis vulgaris
and MS [18]. There are reports of association between
morphea and viral hepatitis C [19].
Regarding differential diagnosis, several disorders
have raised, and continue to raise, differential diagnostic
difficulties. Therefore, numerous controversies occur
regarding the relationship between superficial morphea
and Pasini-Pierini atrophoderma. Some authors consider
both entities to be similar or even identical, especially
regarding the atrophic phase of morphea [20, 21], whereas
other authors distinguish between the two diseases. This
hypothesis is sustained not only by the anomaly of the
elastic fibers, the sclerosis of collagen bundles, and the
presence of active inflammation in the regressed lesion of
superficial morphea, but also by "the Sign of the rock"
that is characteristic for atrophoderma [22-24]. The most
important differential diagnosis regarding morphea
lesions is lichen sclerosus et atrophicus. Lichen sclerosus
et atrophicus represents a different entity, characterized
histo-pathologically by epidermal thinning or atrophy,
follicular hyperkeratosis, vacuolar change of the basal
layer, dermal edema, and marked loss of elastic fibers
[25-27]. The diagnosis of morphea is primarily based on
cutaneous biopsy of the lesions performed for
histopathological examination. The histopathological
examination reveals the presence of thick bundles of
collagen in the dermis. In superficial morphea, the
modifications of collagen fibers can be observed in the
papillary dermis and possibly in the superficial reticular
dermis, while in the classical form of morphea, the
excessive deposition of collagen bundles are also visible
in the reticular and deep dermis. The histopathological
examination must also specify the density of the
fibroblasts and the density of elastic fibers, which can be
performed after special colorations with Verhoeff – Van
Gieson (VVG), Orceine, and Trichrome [27, 28]. The
biopsy should be performed taking into account the
resulting ulceration that can be difficult to treat and which
can even become infected.
Morphea is an autoimmune inflammatory disorder in
which the cutaneous atrophy begins to evolve after the
inflammation phase fades. The treatment is often local
and includes phototherapy. In more severe cases, systemic
therapy may be instituted to prevent (at least in part)
massive involvement of the skin and subcutaneous tissue,
related to major disfigurement and functional impairment.
The most responsive forms of morphea to therapeutic
effects are recent lesions with inflammatory signs. In such
cases, topical treatment and phototherapy can improve the
erythema and the regrowth of the hair follicles. In the
active disease stage, the treatment aim is to limit
formation of new plaques. Topical treatment options
include high potency corticosteroids with their well48

studied adverse reactions and microbiome changes [2931], topical calcineurin inhibitors, and topical vitamin D
analogues [32-35]. Tacrolimus, a calcineurin inhibitor,
has been shown to inhibit development of fibroblasts in
vitro and in vivo [36-38], leading to a successful
management in superficial new plaques of morphea.
Phototherapy has been used as monotherapy or in
combination with topical medication. Long wavelengths
such as ultraviolet type A (320-400nm) are beneficial in
the treatment of sclerotic disorders, due to capability to
penetrate under the epidermis layer, into the subcutis.
Ultraviolet light type B such as UVB or narrowband UVB
(280-315) has the penetrability level reaching the
papillary dermis. The risk involved in using this type of
treatment includes sunburn, erythema, and blistering. It
has been proposed that UV increases the production of
interferon gamma (which has the ability to decrease the
synthesis of collagen) and also decreases collagen I and
III from the morpheic lesions (through decreasing its
synthesis) [37, 38]. Another effect of UV light in sclerotic
diseases is related to the action of increasing collagenase
enzymes [39-41] that induce collagen breakdown.
Phototherapy represents one of the most common
treatments in morphea taking into account the clinical
outcomes. Exposure of the cutaneous lesions to ultraviolet
light has been proven beneficial over time. Mechanisms
involving the decrease of collagen production or the
increase in collagen enzymes have been observed in many
studies. Presumably, fibroblasts augment the production
of metalloproteinase extracellular matrix after exposure to
UVA light [42, 43]. Another important finding suggests
that exposure to UVA light decreases inflammatory cells
that sustain the clinical expression of this disorder.
Several studies show that after UVA radiation, there is a
decrease in inflammatory cells as lymphocytic T cells,
mast cells, and Langerhans cells [44]. UVB has shown the
potential to enhance the receptor for α-melanocytestimulating hormone, causing the release of
metalloproteinase extracellular matrix [45]. Systemic
therapy in morphea is usually necessary in patients with
severe and disfiguring disease forms, or in patients
diagnosed with generalized acute or progressive morphea.
The use of methotrexate on such patients is required, but
relapses may occur at cessation of the medication. It may
be useful to combine methotrexate with systemic steroids.
Depth of lesion, lesion localization, and cosmetic
considerations are important factors contributing to a
lower quality of life in patients diagnosed with morphea.
Physical and occupational therapy are required when
generalized or deep morphea (affecting the subcutaneous
fat or muscles) occur. Another option for patients who
suffer from advanced cosmetic lesions (often on the face)
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is represented by filler therapy. In patients with severe
contractures, surgery may represent a viable therapeutic
option [44-46].

Conclusions
Morphea is an autoimmune inflammatory skin
condition which affects both children and adults. It is
characterized by an acute phase which involves an
inflammatory process of the skin, in which the active
plaques are increasing in size and present an indurated
erythematous, violaceus border. Over time, the
inflammation decreases in the center of the lesion and
atrophy appears. The histopathological appearance of the
lesions depends on the stage of the disease. The
inflammatory infiltrate, localized perivascular and into the
interstitial tissue, consists of T lymphocytes, mast cells,
eosinophils and plasma cells. When sclerosis occurs, the
histopathology examination reveals thickened collagen
bundles into the papillary and reticular dermis up to the
subcutaneous layer. The course of the disease is mainly
chronic even though it is often asymptomatic. The most
important characteristic for treatment is the ability to
reduce the local inflammatory reaction and to stop the
progression of the disease. In terms of atrophic lesions,
treatments are limited, and sclerosis is very difficult to
treat. Surgery of the lesions is an option as well as
injections of fillers.
Our experience with the excimer laser, based on UVB
308 nm showed an important beneficial therapeutic effect
mainly on the inflammatory lesions, characterized by
erythematous plaques or edematous patches.
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